For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Mineralys Therapeutics Inc (NASDAQ: MLYS) closed the day trading at $13.21 down -0.23% from the previous closing price of $13.24. In other words, the price has decreased by -$0.23 from its previous closing price. On the day, 0.5 million shares were traded. MLYS stock price reached its highest trading level at $13.615 during the session, while it also had its lowest trading level at $12.94.
Ratios:
For a better understanding of MLYS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.02 and its Current Ratio is at 14.02. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 10, 2024, initiated with a Buy rating and assigned the stock a target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.
On March 07, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $27.Wells Fargo initiated its Overweight rating on March 07, 2023, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 14 ’25 when Rodman David Malcom sold 11,366 shares for $14.53 per share. The transaction valued at 165,185 led to the insider holds 111,686 shares of the business.
Levy Adam Scott sold 10,757 shares of MLYS for $129,684 on Apr 11 ’25. The CFO and Secretary now owns 215,340 shares after completing the transaction at $12.06 per share. On Apr 11 ’25, another insider, Congleton Jon, who serves as the Chief Executive Officer of the company, sold 15,319 shares for $12.19 each. As a result, the insider received 186,803 and left with 862,289 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 866097792 and an Enterprise Value of 460141760.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.09, which has changed by 0.16285217 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 5.37%, while the 200-Day Moving Average is calculated to be 7.29%.
Shares Statistics:
Over the past 3-months, MLYS traded about 1.10M shares per day on average, while over the past 10 days, MLYS traded about 914120 shares per day. A total of 49.82M shares are outstanding, with a floating share count of 38.28M. Insiders hold about 40.99% of the company’s shares, while institutions hold 44.69% stake in the company. Shares short for MLYS as of 1743379200 were 4708751 with a Short Ratio of 4.30, compared to 1740700800 on 2013841. Therefore, it implies a Short% of Shares Outstanding of 4708751 and a Short% of Float of 10.01.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
